Compare stocks

ELTX vs SLGL

Elicio Therapeutics, Inc. Common Stock and Sol-Gel Technologies Ltd. Ordinary Shares

Compare the businesses

Elicio Therapeutics, Inc. Common Stock

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Open ELTX dashboard ↗

Sol-Gel Technologies Ltd. Ordinary Shares

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Open SLGL dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗